Rachel Foot, MD
Pulmonary Disease · Cincinnati, OHNPI 1306102801
Payments from drug & device makers
What this record shows
This record is dominated by education: $4,000 of the $5,296 with a category attached, or 75.5%. Intuitive Surgical accounts for 93.6% of it on its own, with 9 other manufacturers making up the rest. 2025 is the largest year on record at $5,035, more than ten times the $19 reported in 2021.
Across 20 payments — averaging $264.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$5K
- Abbott$94
- Jazz Pharmaceuticals Inc.$56
- Baxter Healthcare$47
- Regeneron Healthcare Solutions, Inc.$37
- Harmony Biosciences LLC$33
- plus $71 from 4 others
Across 24 payments — averaging $4086.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$49K
- GSK$49K
What the payments were for
- Travel & lodging$94218%
- Food & beverage$3547%
- Education$4,00076%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 8 | $4,959 |
| Abbott | 1 | $94 |
| Jazz Pharmaceuticals Inc. | 2 | $56 |
| Baxter Healthcare | 2 | $47 |
| Regeneron Healthcare Solutions, Inc. | 2 | $37 |
| Harmony Biosciences LLC | 1 | $33 |
| Mallinckrodt Hospital Products Inc. | 1 | $20 |
| Agile Therapeutics, Inc. | 1 | $19 |
| GSK | 1 | $17 |
| Actelion Pharmaceuticals US, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$4,912
How this compares
$5,296 in reported general payments places this provider in the 70th percentile of 571 pulmonary disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pirfenidone | 27 | $33,414 |
| Mycophenolate Mofetil | 86 | $12,613 |
| Breo ElliptaFluticasone/Vilanterol | 28 | $12,350 |
| Spiriva RespimatTiotropium Bromide | 16 | $11,151 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 21 | $9,804 |
| SymbicortBudesonide/Formoterol Fumarate | 18 | $5,840 |
| DuleraMometasone/Formoterol | 12 | $4,250 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 36 | $3,271 |
| Prednisone | 124 | $590 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 27 | $489 |
| Azathioprine | 11 | $284 |
| Azelastine Hcl | 15 | $254 |
| Azithromycin | 13 | $229 |
| Montelukast Sodium | 37 | $218 |
| Famotidine | 15 | $119 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKBreo Ellipta | $17 | $12,35028 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 571 pulmonary disease providers in Ohio.
Other pulmonary disease in Cincinnati
- Robert BaughmanCincinnati$640K
- Bruce CorserCincinnati$502K
- Mohammad SheattCincinnati$389K
- Jean ElwingCincinnati$320K
- Bruce TrapnellCincinnati$92K
- Arun JoseCincinnati$56K
- Francis McCormackCincinnati$19K
- Joseph KhabbazaAkron$655K
- Kristin HighlandCleveland$551K
- Jason StieneckerLima$397K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.